Clinical Trials Browser

Phase 1/2 × Active not recruiting × Gemcitabine × Clear all

NCT05616624 2026-04-15

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Phase 1/2 Active not recruiting

31 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04216316 2026-04-13

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

12 enrolled 25 charts

Thoracic

Lung Neoplasms

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1/2 Active not recruiting

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04542824 2026-04-08

EPCORE™ NHL-3

Phase 1/2 Active not recruiting

78 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-04-08

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

543 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05181462 2026-04-06

TRIFOUR

Phase 1/2 Active not recruiting

117 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05229497 2026-03-09

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Phase 1/2 Active not recruiting

154 enrolled

Advanced Malignant Tumors

NCT06646055 2026-03-09

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Phase 1/2 Active not recruiting

110 enrolled

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT02422381 2026-02-18

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Active not recruiting

16 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03598595 2026-02-04

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

Phase 1/2 Active not recruiting

31 enrolled

Sarcoma

Osteosarcoma

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Phase 1/2 Active not recruiting

54 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04396821 2025-12-17

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

150 enrolled

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms

NCT02481635 2025-12-08

A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer

Phase 1/2 Active not recruiting

30 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02420847 2025-11-10

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1/2 Active not recruiting

57 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04821284 2025-11-04

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Phase 1/2 Active not recruiting

120 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05669482 2025-09-02

RAMP205

Phase 1/2 Active not recruiting

40 enrolled

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT04179162 2025-06-13

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Phase 1/2 Active not recruiting

54 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT02202772 2025-02-24

CGC

Phase 1/2 Active not recruiting

51 enrolled

Carcinoma, Neoplasms, Recurrence

NCT04827953 2024-12-30

NUMANTIA

Phase 1/2 Active not recruiting

28 enrolled

Gastrointestinal

Pancreatic Ductal Adenocarcinoma